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A case of West Nile virus (WNV) infection was reported 
in the Algarve region, Portugal, in the first week 
of September 2015. WNV is known to circulate in 
Portugal, with occasional reports in horses and birds 
(2004 to 2011) and very sporadically human cases (in 
2004 and in 2010). Here we present the clinical and 
laboratory aspects related to the first human case of 
West Nile neuroinvasive disease reported in Portugal.
In September 2015, a case of West Nile neuroinva-
sive disease was reported in a patient with neurologi-
cal symptoms by molecular and serological methods 
at the National Health Institute (INSA), the reference 
laboratory for the diagnosis of flaviviruses in Portugal. 
Although all samples were negative for the presence of 
West Nile virus (WNV) RNA, positive immunofluores-
cence results were confirmed by virus neutralisation 
tests meeting the European Union case definition for 
WNV infections. 
Case description
On 21 July 2015 a man in his 70s was assessed in the 
emergency room of Faro Hospital with a history of six 
days of high fever (≥ 38.5 °C), headache and altered 
state of consciousness with progressive prostration, 
drowsiness and lethargy, confusion, gait difficulty and 
urinary retention. A macular rash was seen on arms 
and thighs.
The patient, who lives in a rural area in Almancil, 
Algarve had frequent contact with animals (chickens, 
pigs, sheep and horses), had not travelled abroad in 
the previous year and reported that he had never been 
vaccinated against flaviviruses (yellow fever, tick-borne 
encephalitis or Japanese encephalitis virus). 
The laboratory findings in the hospital showed hae-
moglobin 12.4 mg/dL (norm: 13–17 g/dL), leukocytes 
14.8 × 109/L (norm: 4–10 × 109/L) and C-reactive pro-
tein 40 mg/L (norm: < 5 mg/L). Cerebrospinal fluid (CSF) 
showed 103 cells/mm3 (norm: < 6 cells/mm3) with a pre-
dominance of lymphocytes, 143 mg/dL protein (norm: 
15–60 mg/dL) and 58 mg/dL glucose (norm: 40–60 mg/
dL). 
At the emergency room, viral meningoencephalitis, 
rickettsial meningoencephalitis or bacterial meningitis 
diagnosis were considered and the patient was empiri-
cally treated with ceftriaxone (2 g, 12/12 h for 14 days) 
and doxycycline (100 mg, 12/12 h for 7 days). CSF sam-
ple molecular analyses were requested for neurotropic 
viruses (herpes simplex viruses (1 and 2), Varicella zos-
ter virus, Epstein-Barr virus, cytomegalovirus, human 
herpes virus (6, 7 and 8) and enterovirus) and arbovi-
ruses (Toscana virus and WNV). Serological analysis 
for Borrelia burgdorferi, Coxiella burnetii, Brucella sp., 
Epstein-Barr virus, Hepatitis B and C viruses, human-
immunodeficiency virus (1 and 2), Mycoplasma pneu-
monia, Rickettsia conorii and Treponema pallidum were 
also requested. All results became negative except for 
C. burnetii IgG 200 (cut-off: 200), and serological anal-
ysis were requested for Toscana virus and WNV. 
After 14 days, the patient had a good outcome and 
was discharged with minimal residual neurological dis-
ease, i.e. some slowing in speech and action. Thirty-
four days after the onset of symptoms he returned for 
further evaluation and blood tests, and neurological 
examination showed full recovery.
Molecular and serological diagnostics
In the National Institute of Health (INSA), a CSF sam-
ple taken on day 6 after symptoms onset was negative 
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for West Nile virus (WNV) in a RT-PCR specific for WNV 
lineages 1 and 2 [1]. A urine sample collected on day 
34 after symptom onset was also negative by real-time 
RT-PCR [1,2]. Both samples were also negative when 
tested by generic pan-flavivirus conventional RT-PCR 
[3].
A serum sample taken on day 16 after symptom onset 
was tested by an in–house immunofluorescence assay 
was positive for WNV-specific IgM with a titre of 1,024 
(cut-off: 16) and IgG with a titre of 2,048 (cut-off:  32). 
A second serum sample taken on day 34 after symp-
tom onset showed a WNV-specific IgM titre of 64 and 
IgG titre of 4,096. Both serum samples were also 
subjected to immunofluorescence assays for immu-
noglobulins specific to other flaviviruses, such as yel-
low fever, tick-borne encephalitis, Dengue, Zika and 
Japanese encephalitis virus. All were negative for IgM 
and presented IgG cross-reaction. A WNV-specific IgM 
antibody response in CSF, a criterion for case confirma-
tion, was not tested due to the lack of available sam-
ples after PCR diagnosis.
The serum samples from day 16 and 34 were tested by 
microneutralisation assay. Replicates of twofold dilu-
tions of the inactivated test sera were incubated with 
100 TCID50 of WNV (strain Egypt 101) at 37 °C for 1 hour 
in 96-well microtitre plates. Vero E6 cells were added 
(2 × 104/well) and plates were incubated at 37 °C under 
5% CO2. Plates were examined microscopically for cyto-
pathic effects at 4 days post addition of cells. Standard 
positive (West Nile (strain Eg 101) immune mouse ascy-
tis fluid, CDC, Atlanta) and negative sera were included 
in the assays. Virus used in each run of the test was 
back-titrated to confirm the validity of the test. Titres 
were assigned arithmetically as the dilution of serum 
giving a 50% neutralisation endpoint. Serum neutral-
ising antibody titres of 10 or higher were considered 
significant. Microneutralisation assays of both serum 
samples were positive to a titre of 2,560.
Background
WNV is the most widely distributed mosquito-transmit-
ted flavivirus in the world, and the aetiological agent 
of West Nile fever and West Nile neuroinvasive disease 
(WNND) [4]. The virus is maintained in nature in enzo-
otic cycles involving ornithophilic mosquitoes, mainly 
Culex species, as primary vectors and some species of 
birds as primary reservoirs.
WNV transmission via blood transfusion or organ trans-
plantation is a public health threat because WNV dis-
ease symptoms are estimated to occur in only about 
20% of infected people (of those, less than 1% may 
develop WNND). Most infections are asymptomatic 
(80%) and asymptomatic viraemic donors can transmit 
the virus to immunocompromised or vulnerable recipi-
ents [5]. The acknowledgement of the risk of infected 
blood donations in the affected areas and the emer-
gence of WNV in Europe in the past 10 years prompted 
the European Commission to release a preparedness 
plan for WNV and blood safety in 2012 [6].
WNV is known to circulate in Portugal with frequent 
detections in horses and birds [7]. INSA performs ref-
erence laboratory diagnosis of flaviviruses in Portugal 
and previously identified a probable human case in 
2010 [8], triggering a WNV survey in horses living in 
the same area. The survey identified two WNV-positive 
horses [7]. The first confirmed human cases were diag-
nosed in two tourists in Ireland after a trip to Algarve in 
2004 [9]; they had acquired the infection in the proxim-
ity of the human case identified this year.
Public health measures
The patient reported here represents the first serum-
positive case to date in Portugal. After the communi-
cation of the clinical suspicion of a probable case of 
WNND, clinical, epidemiological and serological sur-
veillance was implemented by the local health authori-
ties in order to assess the possible presence of WNV in 
susceptible species in the area [10].
Although the detection of viral RNA is an unambiguous 
prove of WNV infection, it is known to be challenging 
in patients with symptomatic infections because virae-
mia can be low or absent at the time of symptom onset 
[2]. The negative PCR results in CSF and urine were not 
unexpected seeing as the samples were collected after 
the beginning of symptoms. The positive immunofluo-
rescence results were confirmed by virus neutralisation 
test to ascertain the case confirmation according to the 
European Union case definition for WNV infections [11].
On 3 September, the General Directorate of Veterinary 
(DGAV; Direcção Geral de Alimentação e Veterinária, 
Ministério da Agricultura e do Mar) reported three new 
outbreaks in horses in Loulé, Algarve municipality, and 
so far, four of 82 horses analysed were positive for 
WNV infection [12].
The Algarve region possesses a large a coastal area 
characterised by marshlands, salt marshes, small 
islands, dunes and beaches. Several wetlands and bird 
sanctuaries are present. Fishery, aquaculture and salt 
extraction are important human activities, as is tour-
ism particularly in summer. A nationwide vector sur-
veillance programme (REVIVE) has covered the Algarve 
region since 2008 [13]. 
Conclusion
Veterinary, human and vector surveillance was initi-
ated in the Algarve municipality after the laboratory 
report of the WNND human case and is still ongoing. 
This case highlights the essential role of laboratory 
diagnostics for early detection and implementation of 
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